Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Co-Diagnostics (0A50) Share Price & Analysis

0 Followers

0A50 Stock Chart & Stats

$0.26-$0.01(-3.02%)
At close: 4:30 PM GMT
$0.5$1$1.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.24 - $0.27
52-Week Range
$0.24 - $13.55
Previous Close
$0.27
Volume
N/A
Average Volume (3M)
111.74K
Market Cap
$2.92M
Enterprise Value
$7.56M
Total Cash (Recent Filing)
$714.80K
Total Debt (Recent Filing)
$1.56M
Price to Earnings (P/E)
―
Beta
1.21
Next Earnings
Mar 25, 2027 (Est.)
EPS Estimate
-0.27
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Regulatory And Clinical Progress

The completed analytical and clinical work, together with the dual FDA submission, advances Co-Diagnostics toward potential commercialization of its multiplex respiratory assay. Regulatory progress can reduce development uncertainty and create a foundation for broader adoption if authorization and market execution follow.

Operating Expense Discipline

Lower operating expenses and a narrower adjusted EBITDA loss show that management has begun aligning spending with the company’s current scale. Continued cost discipline could extend the usefulness of available resources and improve operating leverage if regulatory milestones convert into revenue.

Low Balance-sheet Leverage

Modest debt relative to equity limits the burden of scheduled interest and principal obligations compared with more highly leveraged biotechnology companies. This provides some financial flexibility for commercialization and development, although the benefit is tempered by the company’s shrinking capital base.

Bears Say

Minimal Revenue And Severe Losses

The collapse in revenue leaves the business far below the scale needed to support its diagnostic development infrastructure. Negative gross profit and exceptionally deep net losses indicate that current sales do not cover direct costs or operating expenses, making successful commercialization or major cost reduction essential.

Persistent Cash Burn And Limited Liquidity

Sustained operating cash consumption, combined with the sharp decline in cash, materially reduces the company’s runway while it continues funding regulatory, clinical, and platform initiatives. Without improved cash generation or additional funding, liquidity pressure could constrain execution over the coming quarters.

Financing And Dilution Risk

The structured financing provides near-term liquidity but creates substantial obligations through weekly repayments and security over company assets. Convertible features, commitment shares, and ATM repayment priorities can increase dilution and limit financial flexibility while revenue remains too small to fund operations.

Co-Diagnostics News

0A50 FAQ

What was Co-Diagnostics’s price range in the past 12 months?
Co-Diagnostics lowest share price was $0.24 and its highest was $13.55 in the past 12 months.
What is Co-Diagnostics’s market cap?
Co-Diagnostics’s market cap is $2.92M.
When is Co-Diagnostics’s upcoming earnings report date?
Co-Diagnostics’s next earnings report is estimated for Mar 25, 2027 (not yet confirmed), which is in 132 days.
How were Co-Diagnostics’s earnings last quarter?
Co-Diagnostics released its earnings results on Nov 10, 2026. The company reported -$1.01 earnings per share for the quarter, beating the consensus estimate of -$1.25 by $0.24.
Is Co-Diagnostics overvalued?
According to Wall Street analysts Co-Diagnostics’s price is currently Undervalued.
Does Co-Diagnostics pay dividends?
Co-Diagnostics does not currently pay dividends.
What is Co-Diagnostics’s EPS estimate?
Co-Diagnostics’s EPS estimate is -0.27.
How many shares outstanding does Co-Diagnostics have?
Co-Diagnostics has 10,512,190 shares outstanding.
What happened to Co-Diagnostics’s price movement after its last earnings report?
Co-Diagnostics reported an EPS of -$1.01 in its last earnings report, beating expectations of -$1.25. Following the earnings report the stock price went down -19.062%.
Which hedge fund is a major shareholder of Co-Diagnostics?
Currently, no hedge funds are holding shares in GB:0A50
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology